Navigation Links
XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
Date:10/16/2007

Company Also to Host Drug-Eluting Stent Symposium and Analyst Webcast

MENLO PARK, Calif., Oct. 16 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today announced that 2-year data from the CUSTOM I trial and 1-year data from the CUSTOM II trial of the company's investigational Custom NX(R) drug-eluting stent (DES) system will be presented at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., which is taking place October 20 to 25.

In addition, the company will conduct a number of activities during the meeting including an analyst webcast and teleconference to review the CUSTOM I and CUSTOM II clinical data, an evening drug-eluting stent symposium, and an exhibition at booth 6097 on Level 2 of the Washington Convention Center.

Schedule of Events

Sunday, October 21

Event: The Drug-Eluting Stent Summit: The XTENT CUSTOM Biolimus-Eluting

Modular Stent Program (Focus on Multivessel and Diffuse Disease)

Pieter Stella, M.D., Director of Cardiology, University Medical Center,

Utrecht, Netherlands, will present a historical overview and current

perspective on the treatment of multivessel coronary disease and the

treatment of long lesions. An overview of the Custom NX(R) DES System with

respect to the treatment of multivessel and diffuse disease will be

discussed, along with the one-year follow-up results of the CUSTOM II

Trial.

Time/Location: 3:16-3:26 p.m. EDT; Ballroom C, 3rd Floor, Washington

Convention Center

Event: Evening Symposium -- Delivering Safety to Today's Patients

Professor Eberhard Grube, M.D., Chief of Cardiology at the HELIOS Heart

Center in Siebgurg, Germany and principal investigator of the CUSTOM I and

II clinical trials, will review the results to date from Biolimus A9(R)

DES clinical trials and registries. Professor Grube will present two-year

results from the CUSTOM I clinical trial and one-year results from the

CUSTOM II clinical trial.

Bernard de Bruyne, M.D. Ph.D, Cardiovascular Center, OLV Hospital in

Aalst, Belgium, will provide an overview of the Custom NX technology in a

presentation titled "XTENT Custom NX DES Systems: A Novel Approach to the

Percutaneous Treatment of Coronary Artery Disease (CAD)."

Time/Location: 8:00-10:00 p.m. EDT; Renaissance Washington, D.C. Hotel,

Grand Ballroom, 999 Ninth Street NW

Monday, October 22

Event: Analyst Webcast and Teleconference on CUSTOM I and CUSTOM II Data

XTENT will host a webcast and teleconference call to review the CUSTOM I

and CUSTOM II data presented on Sunday. The teleconference and slide

presentation can be accessed via the investor relations section of the

company's website at http://investor.xtentinc.com/events.cfm or by calling

888-663-2258 (from the U.S.), 913-312-1277 (international). Please dial in

or access the website five to ten minutes prior to the beginning of the

call. The webcast will be archived on the website for a minimum of three

months, and can be accessed at the investor relations portion of the

company's website at http://investor.xtentinc.com

Time/Location: 7:00 a.m. EDT

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT Custom NX DES Systems have not been approved for sale by any regulatory authority.

Information about XTENT is available at our website at http://www.xtentinc.com.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. XTENT Announces Promising Six-Month Custom II Trial Data Presented at EuroPCR Meeting
2. The Past, Present and Future of HLA Typing
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
Breaking Medicine News(10 mins):